Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:BTGGF NYSE:CRL NASDAQ:EXAS NASDAQ:INCY NASDAQ:PPD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTGGFBitcoin Group$63.22$63.22$63.22▼$63.22$24.43B0.26279 shsN/ACRLCharles River Laboratories International$159.78-2.4%$144.87$91.86▼$254.15$8.04B1.491.03 million shs518,978 shsEXASExact Sciences$51.91-2.6%$54.36$39.97▼$72.83$9.79B0.952.58 million shs1.74 million shsINCYIncyte$68.59-2.5%$66.23$53.56▼$83.95$13.62B0.681.95 million shs1.09 million shsPPDPPD$47.28$47.27$31.54▼$47.41$16.61B1.961.91 million shsN/AMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTGGFBitcoin Group0.00%0.00%0.00%0.00%+3.36%CRLCharles River Laboratories International-2.36%+1.69%+5.80%+60.49%-21.18%EXASExact Sciences-2.64%-1.71%-6.74%+16.78%+14.52%INCYIncyte-2.49%+0.19%-0.38%+20.61%+12.94%PPDPPD0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBTGGFBitcoin GroupN/AN/AN/AN/AN/AN/AN/AN/ACRLCharles River Laboratories International4.5568 of 5 stars2.15.00.04.72.92.51.9EXASExact Sciences4.7686 of 5 stars3.55.00.04.73.42.50.6INCYIncyte4.7297 of 5 stars2.15.00.02.83.23.33.1PPDPPDN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBTGGFBitcoin Group 0.00N/AN/AN/ACRLCharles River Laboratories International 2.25Hold$174.549.24% UpsideEXASExact Sciences 2.95Moderate Buy$70.5035.81% UpsideINCYIncyte 2.22Hold$74.538.67% UpsidePPDPPD 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest EXAS, BTGGF, INCY, CRL, and PPD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/9/2025CRLCharles River Laboratories InternationalEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$170.00 ➝ $180.007/9/2025CRLCharles River Laboratories InternationalCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$150.00 ➝ $200.007/8/2025EXASExact SciencesEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$66.00 ➝ $68.006/24/2025EXASExact SciencesBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$75.00 ➝ $65.006/23/2025INCYIncyteRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetSector Perform ➝ Sector Perform$67.006/16/2025INCYIncyteStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$75.00 ➝ $107.006/3/2025INCYIncyteCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy6/3/2025INCYIncyteUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$61.005/27/2025INCYIncyteTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$72.00 ➝ $73.005/23/2025CRLCharles River Laboratories InternationalRedburn AtlanticSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$188.00 ➝ $182.005/14/2025CRLCharles River Laboratories InternationalCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBTGGFBitcoin GroupN/AN/AN/AN/AN/AN/ACRLCharles River Laboratories International$4.05B1.94$21.19 per share7.54$67.80 per share2.36EXASExact Sciences$2.83B3.46$5.48 per share9.47$12.98 per share4.00INCYIncyte$4.24B3.13$0.54 per share127.06$17.90 per share3.83PPDPPD$4.68B3.55$1.99 per share23.71($1.21) per share-39.07Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBTGGFBitcoin GroupN/AN/A0.00∞N/AN/AN/AN/AN/ACRLCharles River Laboratories International$22.20M-$0.65N/A14.535.54-0.66%15.19%6.93%8/6/2025 (Estimated)EXASExact Sciences-$1.03B-$5.51N/A103.8211.39-36.06%-3.75%-1.68%7/30/2025 (Estimated)INCYIncyte$32.62M$0.32214.3510.490.590.48%2.77%1.77%7/29/2025 (Estimated)PPDPPD$153.69M$1.0047.2825.982.116.11%-89.48%7.94%N/ALatest EXAS, BTGGF, INCY, CRL, and PPD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025CRLCharles River Laboratories International$2.50N/AN/AN/A$983.76 millionN/A7/30/2025Q2 2025EXASExact Sciences-$0.04N/AN/AN/A$774.43 millionN/A7/29/2025Q2 2025INCYIncyte$1.38N/AN/AN/A$1.15 billionN/A5/7/2025Q1 2025CRLCharles River Laboratories International$2.06$2.34+$0.28$0.50$942.34 million$984.17 million5/1/2025Q1 2025EXASExact Sciences-$0.37-$0.21+$0.16-$0.54$688.58 million$706.79 million4/29/2025Q1 2025INCYIncyte$1.01$1.16+$0.15$0.80$996.17 million$1.05 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBTGGFBitcoin GroupN/AN/AN/AN/AN/ACRLCharles River Laboratories InternationalN/AN/AN/AN/AN/AEXASExact SciencesN/AN/AN/AN/AN/AINCYIncyteN/AN/AN/AN/AN/APPDPPDN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBTGGFBitcoin GroupN/AN/AN/ACRLCharles River Laboratories International0.781.431.16EXASExact Sciences0.972.732.38INCYIncyte0.012.042.00PPDPPDN/A1.231.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBTGGFBitcoin GroupN/ACRLCharles River Laboratories International98.91%EXASExact Sciences88.82%INCYIncyte96.97%PPDPPD87.82%Insider OwnershipCompanyInsider OwnershipBTGGFBitcoin GroupN/ACRLCharles River Laboratories International1.30%EXASExact Sciences1.20%INCYIncyte17.80%PPDPPD1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBTGGFBitcoin Group35386.49 millionN/ANot OptionableCRLCharles River Laboratories International20,10049.12 million48.48 millionOptionableEXASExact Sciences7,000188.64 million186.37 millionOptionableINCYIncyte2,617193.57 million159.12 millionOptionablePPDPPD26,000351.40 million344.72 millionNot OptionableEXAS, BTGGF, INCY, CRL, and PPD HeadlinesRecent News About These CompaniesIllinois man arrested in Priceville on drug charges4 hours ago | msn.comPriceville police arrest 23-year-old for driving under influence of drugs4 hours ago | msn.comOxytocin Boosts Mother-Infant Bond in Postpartum DepressionJuly 12 at 2:10 AM | neurosciencenews.comN‘Be vigilant’: Catalytic converter thefts on the riseJuly 11 at 9:08 PM | msn.comSuspect killed in Pueblo officer-involved shooting identifiedJuly 11 at 9:08 PM | msn.comPueblo Police intense stand-off ends with house in flamesJuly 11 at 9:08 PM | krdo.comKArmed suspect arrested after hours-long standoff with Pueblo policeJuly 11 at 4:07 PM | msn.comPPD: Intense stand-off in Pueblo ends peacefullyJuly 11 at 4:07 PM | msn.comNew officer joins PPDJuly 11 at 10:54 AM | paysonroundup.comPMedicaid Reimbursement Boosts Postpartum Depression ScreeningJuly 10 at 5:50 AM | emjreviews.comECan Gut Microbes Improve Postpartum Depression?July 9 at 12:48 AM | psychologytoday.comPWoman arrested in Priceville on elder explotation chargesJuly 9 at 7:48 PM | msn.comPsychedelics For New Moms? All About The Unexpected New Study That Could Transform Postpartum CareJuly 9 at 7:48 PM | womenshealthmag.comWPPD: Man arrested after allegedly throwing chair through bar windowJuly 9 at 7:48 PM | msn.comPueblo police officer shoots at suspect off Glen Royal DriveJuly 9 at 4:12 AM | krdo.comKPolice report armed suspect dies in Pueblo officer-involved shootingJuly 9 at 4:12 AM | msn.comPPD: Armed suspect dies in Pueblo officer-involved shootingJuly 9 at 4:12 AM | msn.comPPD rerouting traffic near Ninth and Creighton after car vs motorcycle crashJuly 9 at 4:12 AM | yahoo.comTwo teenagers taken to the hospital with serious injuries after shootings in PeoriaJuly 7, 2025 | msn.comJuvenile is third person arrested in deadly shooting in PeoriaJuly 7, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeUber and Tesla Surge on Robotaxis, Analyst Touts Texas RidesBy Leo Miller | June 25, 2025View Uber and Tesla Surge on Robotaxis, Analyst Touts Texas RidesTexas Instruments Stock: Congress Likes It, Should You Too?By Thomas Hughes | June 24, 2025View Texas Instruments Stock: Congress Likes It, Should You Too?EXAS, BTGGF, INCY, CRL, and PPD Company DescriptionsBitcoin Group OTCMKTS:BTGGF$63.22 0.00 (0.00%) As of 07/11/2025Bitcoin Group SE, an investment holding company, engages in the cryptocurrency and blockchain businesses worldwide. The company operates a trading platform for the digital currency bitcoin under the Bitcoin.de. It also provides financial services. The company was founded in 2008 and is based in Herford, Germany. Bitcoin Group SE is a subsidiary of Priority AG.Charles River Laboratories International NYSE:CRL$159.78 -3.88 (-2.37%) Closing price 07/11/2025 03:58 PM EasternExtended Trading$159.44 -0.33 (-0.21%) As of 07/11/2025 04:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.Exact Sciences NASDAQ:EXAS$51.91 -1.41 (-2.64%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$51.50 -0.41 (-0.79%) As of 07/11/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.Incyte NASDAQ:INCY$68.59 -1.75 (-2.49%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$68.33 -0.26 (-0.37%) As of 07/11/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.PPD NASDAQ:PPDPPD, Inc., together with its subsidiaries, provides drug development services to the biopharmaceutical industry worldwide. The company operates through two segments, Clinical Development Services and Laboratory Services. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri-and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company has a collaboration with Science 37 to design, build, test, implement, and execute digital trials using Science 37's DCT SaaS-based technology platform. PPD, Inc. was founded in 1985 and is headquartered in Wilmington, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/07 - 07/11 Power Solutions International Poised for 75% Upside The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
